RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
ADC Therapeutics Stock

ADC Therapeutics P/S 2024

ADC Therapeutics P/S

3.66

Ticker

ADCT

ISIN

CH0499880968

WKN

A2PSR8

As of Dec 4, 2024, ADC Therapeutics's P/S ratio stood at 3.66, a 30.71% change from the 2.8 P/S ratio recorded in the previous year.

The ADC Therapeutics P/S history

ADC Therapeutics Aktienanalyse

What does ADC Therapeutics do?

ADC Therapeutics SA is a biopharmaceutical company specializing in the development of antibody-drug conjugates (ADCs) for the treatment of cancer. Founded in 2011, the company is headquartered in Lausanne, Switzerland. ADCs are customized drugs that consist of an antibody and a cytotoxic drug. The antibody is designed to specifically transport the cytotoxic drug to cancer cells and release it there to destroy the cancer cells. ADC Therapeutics uses a proprietary technology platform called Pyrrolobenzodiazepine (PBD) to manufacture ADCs that have high efficacy and improved safety. The company's business model involves developing and commercializing ADCs in various stages of research, clinical development, and market launch, in collaboration with partners from the pharmaceutical industry. ADC Therapeutics focuses on different types of cancer, including solid tumors such as breast cancer, lung cancer, prostate cancer, and colorectal cancer, as well as hematological tumors such as lymphomas and leukemias. The company has several ADC products in clinical development, including Camidanlumab tesirin (Cami) for the treatment of Hodgkin lymphomas and diffuse large B-cell lymphomas, and ADCT-601 for the treatment of solid tumors overexpressing the HORM2 receptor. ADC Therapeutics has also formed partnerships with other companies, such as Genmab, AstraZeneca, Adagene, and BioNTech, to further develop and commercialize its technology and products. The company aims to improve the quality of life for cancer patients worldwide by providing innovative drugs. ADC Therapeutics ist eines der beliebtesten Unternehmen auf Eulerpool.com.

P/S Details

Decoding ADC Therapeutics's P/S Ratio

ADC Therapeutics's Price to Sales (P/S) Ratio is a crucial financial metric that measures the company's market valuation relative to its total sales revenue. It's calculated by dividing the company's market capitalization by its total sales over a specific period. A lower P/S ratio can indicate that the company is undervalued, while a higher ratio may suggest overvaluation.

Year-to-Year Comparison

Comparing ADC Therapeutics's P/S ratio yearly provides insights into how the market perceives the company’s value relative to its sales. An increasing ratio over time can indicate growing investor confidence, while a decreasing trend might reflect concerns about the company’s revenue generation capabilities or market conditions.

Impact on Investments

The P/S ratio is instrumental for investors evaluating ADC Therapeutics's stock. It offers insights into the company’s efficiency in generating sales and its market valuation. Investors use this ratio to compare similar companies within the same industry, aiding in selecting stocks that offer the best value for investment.

Interpreting P/S Ratio Fluctuations

Variations in ADC Therapeutics’s P/S ratio can result from changes in the stock price, sales revenue, or both. Understanding these fluctuations is crucial for investors to evaluate the company’s current valuation and future growth potential, aligning their investment strategies accordingly.

Frequently Asked Questions about ADC Therapeutics stock

What is the price-to-earnings ratio of ADC Therapeutics?

The price-earnings ratio of ADC Therapeutics is currently 3.66.

How has the price-earnings ratio of ADC Therapeutics changed compared to last year?

The price-to-earnings ratio of ADC Therapeutics has increased by 30.71% increased compared to last year.

What consequences does a high price-earnings ratio have for investors?

A high price-to-earnings ratio indicates that the company's stock is relatively expensive and investors may potentially achieve a lower return.

What does a low price-earnings ratio mean?

A low price-earnings ratio means that the company's stock is relatively cheap and investors may potentially achieve a higher return.

Is the price-earnings ratio of ADC Therapeutics high compared to other companies?

Yes, the price-to-earnings ratio of ADC Therapeutics is high compared to other companies.

How does an increase in the price-earnings ratio of ADC Therapeutics affect the company?

An increase in the price-earnings ratio of ADC Therapeutics would lead to a higher market capitalization of the company, which in turn would lead to a higher valuation of the company.

How does a reduction in the price-to-earnings ratio of ADC Therapeutics affect the company?

A decrease in the price-earnings ratio of ADC Therapeutics would result in a lower market capitalization of the company, which in turn would lead to a lower valuation of the company.

What are some factors that influence the price-earnings ratio of ADC Therapeutics?

Some factors that influence the price-earnings ratio of ADC Therapeutics are the company's growth, financial position, industry development, and the overall economic situation.

How much dividend does ADC Therapeutics pay?

Over the past 12 months, ADC Therapeutics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, ADC Therapeutics is expected to pay a dividend of 0 USD.

What is the dividend yield of ADC Therapeutics?

The current dividend yield of ADC Therapeutics is .

When does ADC Therapeutics pay dividends?

ADC Therapeutics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of ADC Therapeutics?

ADC Therapeutics paid dividends every year for the past 0 years.

What is the dividend of ADC Therapeutics?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is ADC Therapeutics located?

ADC Therapeutics is assigned to the 'Health' sector.

Wann musste ich die Aktien von ADC Therapeutics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of ADC Therapeutics from 12/4/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 12/4/2024.

When did ADC Therapeutics pay the last dividend?

The last dividend was paid out on 12/4/2024.

What was the dividend of ADC Therapeutics in the year 2023?

In the year 2023, ADC Therapeutics distributed 0 USD as dividends.

In which currency does ADC Therapeutics pay out the dividend?

The dividends of ADC Therapeutics are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von ADC Therapeutics

Our stock analysis for ADC Therapeutics Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of ADC Therapeutics Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.